Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II/III multi-center, randomized, double-blind, positive control design study to evaluate the efficacy and safety of QHL-108 versus doxorubicin in patients with advanced soft tissue sarcoma

Next Previous
Trial Profile

Phase II/III multi-center, randomized, double-blind, positive control design study to evaluate the efficacy and safety of QHL-108 versus doxorubicin in patients with advanced soft tissue sarcoma

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QHL 108 (Primary) ; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Shanghai Affinity Biopharmaceutical

Most Recent Events

  • 22 Dec 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top